SGS Increases Biopharma Characterization Capabilities
An expansion of laboratory facilities in Geneva, Switzerland expands SGS services for high-order structure analysis.
SGS announced on Aug. 28, 2018 that the company is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland with the addition of a 200-sq.-m laboratory for early and late phase of biopharmaceutical characterization.
Scheduled to open by the end of the third quarter of 2018, the new laboratory will provide services for high-order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC).
When complete, the new laboratory will enable the Geneva facility-which opened in 1991 and is cGMP certified, GLP compliant, and FDA inspected-to offer ICH Q6B physico-chemical characterization of biological products, the company reported in a press announcement.
Source: SGS
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 5th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
